Brief: Cansino Biologics Says Inhaled TB Booster Obtains Clinical Trial Approval In Indonesia
15/05/2025 10:18
May 15 (Reuters) - CanSino Biologics Inc 688185.SS: INHALED TB BOOSTER OBTAINS CLINICAL TRIAL APPROVAL IN INDONESIA Further company coverage: 688185.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025